News Headline Summary

Analysis confirms Johnson and Johnson's (JNJ) Janssen unit's Xarelto has similar efficacy and reduces the incidence of major bleeding by nearly half compared to standard of care in treatment of DVT and PE

20 Sep 2013 - 13:46 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: